[Alberti, K.G., Zimmet, P., Shaw, J. (2005) The metabolic syndrome—a new worldwide definition. Lancet, 366, 1059-1062.10.1016/S0140-6736(05)67402-8]Search in Google Scholar
[Anonīms (2010). Latvijas veselības statistikas gadagrāmata par 2009. gadu [Yearbook of Latvian Health Statistics for 2009]. Rīga: VSMTVA (Veselības statistikas un medicīnas tehnologiju valsts agentūra), 2010 (in Latvian).]Search in Google Scholar
[Anonymous (2011). Procoralan SPC (Summary of Product Characteristics)]Search in Google Scholar
[http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000597/WC500043590.pdf]Search in Google Scholar
[Anonymous (2008). The BEAUTIFUL Study Group. The BEAUTIFUL study: Randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction—baseline characteristics of the study population. Cardiology, 110, 271-282.]Search in Google Scholar
[Balode, I., Jēgere, S., Mintāle, I., Narbute, I., Zakke, I., Latkovskis, G., Ērglis, A. (2010). Current state of angina treatment in the outpatient population and heart rate monitoring survey in Latvia (REALITY Latvia). Proc. Latv. Acad. Sci., Section B, 64(5/6), 194-201.]Search in Google Scholar
[Boden, W.E., O'Rouke, R., Teo, K.T., Hartigan, P.M., Maron, D.J., Kostuk, W.I., Knudston, M., Dada, M., Casperson, P., Harris, C.L., Chaitman, B.R., Shaw, L., Gosselin, G., Navaz, S., Title, L.M. Gau, G., Blaustein, A.S., Booth, D.C., Bates, E.R., Spertus, J.A., Berman, D.S., Mancini, J., Weintraub, W.S. for the COURAGE Trial Research Group. (2007). Optimal Medical Therapy with or without PCI for Stable Coronary Disease. N Engl. J. Med., 356. www.nejm.org. http://www.nejm.org10.1056/NEJMoa070829]Search in Google Scholar
[Bohm, M., Swedberg, K., Komajda, M., Borer, J., Ford, I., Dubost-Brama, A., Lerebous, G., Tavazzi, L., on behalf of the SHIFT investigators (2010). Heart rate as a risk factor in chronic heart failure (SHIFT): The association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet, 376, 886-894.10.1016/S0140-6736(10)61259-7]Search in Google Scholar
[Daly, C.A., Clemens, F., Lopez Sendon, J. L., Tavazzi, L., Boersma, E., Danchin, N., Delahaye, F., Gitt, A., Julian, D., Mulcahy, D., Ruzyllo, W., Thygesen, K., Verheugt, F., Fox K.M. (2005). The initial management of stable angina in Europe, from the Euro Heart Survey: A description of pharmacological management and revascularization strategies initiated with the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina. Eur. Heart J., 26, 1011-1022.10.1093/eurheartj/ehi109]Search in Google Scholar
[Daly, C.A., De Stavola, B., Lopez-Sendon, J. L., Tavazzi, L, Boersma, E., Clemens, F., Danchin, N., Delahaye, F., Gitt, A., Julian, D., Mulcahy, D., Ruzyllo, W., Thygesen, K., Verheugt, F., Fox K.M. (2006). Predicting prognosis in stable angina—results from the Euro Heart Survey of stable angina: Prospective observational study. BMJ, 332, 262-267.10.1136/bmj.38695.605440.AE]Search in Google Scholar
[Daly, C., Tavazzi, L., Fox, K., Euro Heart Survey of Angina Investigators (2008) Inadequate control of heart rate in patients with stable angina: Results from the European Heart Survey. Eur. Heart J., 29 (Abstract Supplement), 204.]Search in Google Scholar
[Diaz, A., Bourassa, M. G., Guertin, M. C., Tardif, J. C. (2005). Long term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur. Heart J., 26(10), 967-974.10.1093/eurheartj/ehi190]Search in Google Scholar
[Ērglis, A., Kalvelis, A., Lejnieks, A., Dzērve, V., Latkovskis, G., Mintāle, I., Zakke, I., Rasa, I. (2007). Kardiovaskulāro slimību (KVS) profilakses vadlīnijas [Guidelines on cardiovascular disease prevention]. Rīga. 45. lpp. (in Latvian).]Search in Google Scholar
[Fox, K., Garcia, M.A.A., Ardissino, D., Buszman, P., Camici, P.G., Crea, F., Daly, C., Backer, G., Hjemdahl, P., Lopes-Sendon, J., Marco, J., Morais, J., Pepper, J., Sechtem, U., Simoons, M., Thygesen, K. (2006). Guidelines on the management of stable angina pectoris. The Task Force on the Managment of Stable Angina Pectoris of the European Society of Cardiology. Eur. Heart J., 27, 341-1381.]Search in Google Scholar
[Fox, K., Ford, I., Steg, P. G., Tendera, M., Robertson, M., Ferrari, R., BEAUTIFUL investigators (2008a) Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL):A subgroup analysis of a randomised controlled trial. Lancet, 372, 817-821.10.1016/S0140-6736(08)61171-X]Search in Google Scholar
[Fox, K., Ford, I., Steg, P. G., Tendera, M., Ferrari, R., BEAUTIFUL investigators (2008b) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial. Lancet, 372, 807-816.10.1016/S0140-6736(08)61170-8]Search in Google Scholar
[Fox, K., Ford, I., Steg, P. G., Tendera, M., Robertson, M., Ferrari, R., BEAUTIFUL investigators (2009) Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic function with limiting angina: A subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur. Heart J., 30, 2337-2345.]Search in Google Scholar
[Gislason, G.H., Rasmussen, J.N., Abildstrom, S.Z., Gadsboll, N., Buch, P., Friberg, J., Rasmussen, S., Kober, L., Stender, S., Madsen, M., and Torp-Pederden, C. (2006). Long term compliance with beta-blockers, angiotensin-converting inhibitors, and statins after acute myocardial infarction. Eur. Heart J., 27, 1153-1158.10.1093/eurheartj/ehi70516399775]Search in Google Scholar
[Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., Gjelsvik, B., Herrmann-Lingen, C., Hoes, A., Humphries, S., Knapton, M., Perk, J., Priori, S.G., Pyorala, K., Reiner, Z., Ruilope, L., Sans-Menendez, S., Reimer, V.S.O., Weissberg, P., Wood, D., Yarnell, Y., Zamorano, J. L. (2007). European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Eur. Heart J., 28, 2375-2414.10.1093/eurheartj/ehm31617726041]Search in Google Scholar
[Leal, J., Luengo-Fernindez, R., Gray, A., Petersen, S., Rayner, M. (2006). Economic burden of cardiovascular diseases in the enlarged European Union. Eur. Heart J., 27(13), 1610-1619.10.1093/eurheartj/ehi733]Search in Google Scholar
[Lopez-Sendon, J., Swedberg, K., McMurray J., Tamargo, J., Maggioni, A.P., Dargie, H.,Tendera, M., Waagstein, F., Kjekshus, J., Lechat, P., Torp-Pedersen, C. (2004). Expert consensus document on ā-adrenergic receptor blockers. The Task Force on Beta-Blockers of the European Society of Cardiology. Eur. Heart J., 25, 1341-1362.10.1016/j.ehj.2004.06.002]Search in Google Scholar
[Mathers, C.D., Loncar, D. (2006). Projections of global mortality and buren of disease from 2002 to 2030. PLoS Med., Nov, 3, e442.10.1371/journal.pmed.0030442]Search in Google Scholar
[Tunstall-Pedoe, H., Kuulasmaa, K., Mahonen, M., Tolonen, H., Ruokokoski, E., Amouyel, P., for the WHO MONICA (monitoring trends and determinants in cardiovascular disease) Project (1999) Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet, 353, 1547-1557.10.1016/S0140-6736(99)04021-0]Search in Google Scholar
[Swedberg, K., Komajda, M., Bohm, M., Borer, J., Ford, I., Dubost-Brama, A., Lerebous, G., Tavazzi, L., on behalf of the SHIFT investigators (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet, 376, 875-885.10.1016/S0140-6736(10)61198-1]Search in Google Scholar